Moderna-Merck melanoma vaccine meets Phase 3 endpoint in late-stage trial
Moderna shares surged as much as 83% in premarket trading after its personalized melanoma vaccine, developed with Merck, delivered a positive late-stage trial result. The first reported Phase 3 success for a personalized cancer vaccine creates a material read-through for Moderna’s oncology pipeline and Merck’s Keytruda franchise, but the commercial and regulatory path still needs to be established.
STOCK PHOTO · TOM FISKThe story
The trial tested intismeran autogene in combination with Merck's Keytruda in patients with melanoma and met its primary endpoint by reducing the risk of recurrence. It is described as the first positive Phase 3 trial for a personalized cancer vaccine, making the result a significant clinical milestone for the field. Moderna's shares rose as much as 83% in premarket New York trading after the news.
The collaboration links Moderna's vaccine platform with Merck's established immunotherapy, Keytruda. For Moderna, the result supports the possibility that its mRNA technology can extend beyond infectious-disease vaccines; for Merck, it could add a personalized-vaccine combination to an important oncology franchise.
Key questions remain about the magnitude of the recurrence reduction, overall-survival data, safety profile, regulatory filing timeline, and the commercial terms of the collaboration, along with the durability of the benefit and manufacturing requirements for individualized treatments.
Our read · Fri, Aug 21
Moderna’s personalized melanoma vaccine, developed with Merck, delivered a positive Phase 3 result; MRK’s Keytruda is part of the combination.
Why. The result strengthens the long-term oncology setup for MRK by pairing Keytruda with the first personalized cancer vaccine to clear a Phase 3 endpoint. The trade remains measured because critical details about the size of the recurrence reduction, safety profile, regulatory timing, and commercial terms have yet to be disclosed, while MRK's existing $65.0B revenue base means the program's eventual contribution must be demonstrated rather than assumed.
Both cases
What could change this view: The setup fails if the full dataset shows a modest or poorly durable benefit, safety problems, difficult individualized manufacturing, or a regulatory and commercial timeline that limits Keytruda’s combination opportunity.
Who reported it · 4
Same arc
Reports linked to this one, newest first. Automatically linked reports may cover a broader event.
Keep reading
Latest on the Wire
AMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackContinue on the Wire →Latest on the Wire
Biohaven reports confirmed BHV-1530 responses in two FGFR3 cancersTrump, Xi and Putin pledge more refined fuel after first trilateral summitSky reserve linked to $518 million in illicit activity, investigation findsBitcoin nears $64,000 as Anthropic IPO lifts Nasdaq futures nearly 2%Continue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseAbout this report
Reported by ZeroHedge as Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success
, . Who answers for this
4 reports from 4 publishers in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →